BMCM
PFE icon

Bryn Mawr Capital Management’s Pfizer PFE Stock Holding History

Bryn Mawr Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Sell
50,715
-28,652
-36% -$763K 0.07% 181
2025
Q4 		$1.98M Buy
79,367
+2,500
+3% +$63K 0.1% 154
2025
Q3 		$1.96M Sell
76,867
-93
-0.1% -$2.29K 0.1% 152
2025
Q2 		$1.87M Buy
76,960
+8,075
+12% +$188K 0.1% 152
2025
Q1 		$1.75M Sell
68,885
-3,248
-5% -$85K 0.1% 149
2024
Q4 		$1.91M Sell
72,133
-12,317
-15% -$334K 0.1% 156
2024
Q3 		$2.44M Sell
84,450
-109,585
-56% -$3.2M 0.13% 138
2024
Q2 		$5.43M Sell
194,035
-6,206
-3% -$171K 0.3% 76
2024
Q1 		$5.56M Buy
200,241
+25,825
+15% +$717K 0.32% 79
2023
Q4 		$5.02M Sell
174,416
-69,173
-28% -$2.09M 0.31% 81
2023
Q3 		$8.08M Buy
243,589
+23,457
+11% +$829K 0.53% 46
2023
Q2 		$8.07M Buy
220,132
+12,114
+6% +$472K 0.76% 35
2023
Q1 		$8.49M Sell
208,018
-7,803
-4% -$337K 0.88% 31
2022
Q4 		$11.1M Buy
215,821
+203,656
+1,674% +$9.76M 1.19% 23
2022
Q3 		$532K Sell
12,165
-70
-0.6% -$3.4K 0.19% 87
2022
Q2 		$641K Sell
12,235
-400
-3% -$20.4K 0.21% 87
2022
Q1 		$654K Buy
12,635
+550
+5% +$28.5K 0.18% 92
2021
Q4 		$714K Sell
12,085
-130
-1% -$6.44K 0.27% 47
2021
Q3 		$525K Buy
12,215
+2,080
+21% +$92.1K 0.24% 54
2021
Q2 		$397K Hold
10,135
– – 0.18% 64
2021
Q1 		$367K Buy
10,135
+49
+0.5% +$1.74K 0.18% 63
2020
Q4 		$371K Sell
10,086
-1,177
-10% -$43.2K 0.18% 61
2020
Q3 		$392K Buy
11,263
+2,073
+23% +$72.7K 0.23% 56
2020
Q2 		$285K Sell
9,190
-3,863
-30% -$131K 0.18% 67
2020
Q1 		$404K Sell
13,053
-70
-0.5% -$2.38K 0.27% 47
2019
Q4 		$488K Buy
13,123
+173
+1% +$6.16K 0.35% 45
2019
Q3 		$441K Sell
12,950
-1,460
-10% -$53.1K 0.37% 45
2019
Q2 		$592K Buy
14,410
+2,618
+22% +$104K 0.5% 37
2019
Q1 		$475K Sell
11,792
-754
-6% -$30.2K 0.43% 40
2018
Q4 		$520K Sell
12,546
-62
-0.5% -$2.57K 0.47% 37
2018
Q3 		$527K Sell
12,608
-632
-5% -$24.3K 0.44% 36
2018
Q2 		$456K Buy
13,240
+188
+1% +$6.42K 0.4% 41
2018
Q1 		$439K Buy
+13,052
New +$449K 0.4% 38
2017
Q4 		– Sell
-12,873
Closed -$436K – 71
2017
Q3 		$436K Buy
+12,873
New +$414K 0.45% 36
2017
Q2 		– Sell
-13,605
Closed -$442K – 83
2017
Q1 		$442K Buy
13,605
+294
+2% +$9.27K 0.45% 40
2016
Q4 		$410K Buy
+13,311
New +$406K 0.42% 42

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Bryn Mawr Capital Management's PFE Position: Q1 2026 in Review

Bryn Mawr Capital Management reduced its Pfizer (PFE) stake by 36% in Q1 2026, selling an estimated $763K and leaving 50,715 shares worth $1.42M. The position accounts for 0.07% of the portfolio, ranked #181.

Bryn Mawr Capital Management first reported a position in PFE in Q4 2016 and has held it in 36 quarters since. The position peaked at $11.1M in Q4 2022. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Bryn Mawr Capital Management held 50,715 shares of Pfizer worth $1.42M as of Q1 2026.
  • Bryn Mawr Capital Management sold 28,652 Pfizer shares in Q1 2026, an estimated $763K.
  • Pfizer made up 0.07% of Bryn Mawr Capital Management's portfolio in Q1 2026, its #181 holding.
  • Bryn Mawr Capital Management first reported a position in Pfizer in Q4 2016 and has held it in 36 quarters since.
  • Bryn Mawr Capital Management's Pfizer position peaked at $11.1M in Q4 2022.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Bryn Mawr Capital Management's 13F filing for Q1 2026, filed 4 May 2026.